Vendor Due Diligence for Generative AI in Healthcare

A clinic-ready vendor due diligence guide with AI contract templates for HIPAA, synthetic data, retention, and explainability.

Generative AI is moving fast in insurance, claims processing, customer engagement, underwriting support, and synthetic data generation. For clinics, that speed creates a very practical question: how do you adopt useful AI-powered workflows without putting protected health information (PHI), patient trust, or HIPAA compliance at risk? The answer is not to avoid AI altogether. The answer is to run stronger data governance, use tighter third-party access controls, and insist on contracts that clearly define what a vendor or insurer may do with your data, models, and outputs.

This guide is designed for operations leaders, practice owners, compliance teams, and business buyers who are evaluating vendors now. It gives you a vendor due diligence checklist, contract language templates, and a practical decision framework for managing generative AI with insurers and third parties. We will also connect the dots to the broader realities of contract clauses and technical controls, because AI risk is never just a legal issue; it is a security, workflow, and reputation issue too.

Pro Tip: If a vendor cannot explain where your data goes, who can access it, how long it is retained, and whether it trains models, treat that as a red flag—not a minor gap.

Why generative AI changes vendor risk for clinics

AI vendors are not “just software vendors” anymore

Traditional software vendors generally store data, process transactions, and maybe integrate with your EHR. Generative AI vendors can do all that and more: infer, summarize, generate, classify, and repurpose data into outputs that may be hard to trace. That means the risk surface expands from ordinary hosting concerns to include prompt leakage, model training on customer content, output hallucinations, and hidden subcontractor dependencies. If you are evaluating a payer, clearinghouse, patient engagement platform, or claims partner using generative AI, you need a stronger lens than the usual security questionnaire.

The market trend is unmistakable. Insurance is rapidly adopting generative AI for underwriting automation, fraud detection, customer engagement, and claim processing, with market forecasts showing strong growth through 2035. That matters to clinics because insurers increasingly touch clinical workflows, prior authorization, claims review, and patient communications. As insurers modernize, clinics will be asked to exchange more data with AI-enabled systems, which makes AI-specific contractual guardrails a necessity, not a nice-to-have.

Healthcare data raises the stakes beyond ordinary PII

In a clinic setting, the vendor risk is amplified because the data is not just personally identifiable information; it is often PHI, billing data, eligibility data, diagnostic data, and operational notes that reveal health status. Once that data enters an AI workflow, you need to know whether it is being used to improve a model, generate synthetic training data, support human review, or feed a third-party analytics layer. Even if a vendor claims the system is “privacy-safe,” you still need to verify the mechanism. Like clinical trials with vehicle arms, you should compare the AI feature against a known baseline and ask what is actually changing—because “AI-powered” can hide many different processing models.

Regulatory expectations are becoming more specific

Regulators and industry bodies are increasingly focused on transparency, accountability, explainability, and data minimization. For clinics, that means the question is no longer merely whether a vendor signs a BAA. You need to know whether the vendor can support access controls, audit trails, retention limits, incident reporting, and meaningful human oversight. The more a vendor’s AI system influences patient communications, eligibility decisions, or revenue cycle actions, the more you should demand evidence that the system is monitored and can be explained. This is the same logic you would use in validation pipelines for clinical decision support: test, monitor, document, and re-test.

The vendor due diligence checklist clinics should use

1. Define the AI use case before you review the vendor

Before you send a questionnaire, define exactly what the vendor or insurer’s generative AI will do. Is it drafting patient emails, summarizing claims, classifying prior authorization requests, generating synthetic data, or powering a chatbot? Each use case has different compliance and operational impacts, and a one-size-fits-all risk review will miss the details that matter. This is similar to choosing the right operational strategy in specialized AI orchestration: if the workflow is vague, the controls will be vague too.

A good scope statement should identify data categories, user groups, output recipients, and whether humans review outputs before they affect patient care or billing. If the vendor cannot align to a narrowly defined use case, the integration may be too immature for production use. Clinics should also insist that any expansion of scope triggers a new review, rather than silently extending the original agreement.

2. Ask where the data lives, moves, and persists

Your due diligence should map the full data lifecycle: ingestion, processing, storage, backups, logs, model prompts, vector databases, analytics, and deletion. Generative AI systems can create “shadow copies” of content in logs, embeddings, caches, and support artifacts. If the vendor cannot tell you where PHI is stored and whether it is replicated across regions or shared with subprocessors, that is a problem. This is the same reason organizations review third-party access pathways as carefully as perimeter defenses.

Ask specifically about retention windows for prompts, outputs, human review notes, training corpora, and telemetry. Require written answers, not marketing language. If the vendor says retention is “industry standard,” ask them to define the standard and whether customers can shorten it.

3. Verify security controls and administrative boundaries

Security controls should include role-based access control, strong authentication, encryption in transit and at rest, logging, segregation of customer data, and incident response commitments. But for generative AI, you also need controls around prompt visibility, output export, admin console access, and support access. Many AI incidents happen because internal users, contractors, or support teams have broader access than the customer expected. A well-designed control model should be as disciplined as the one used for secure pairing practices: explicit authorization, minimal trust, and clear revocation paths.

For clinics, it is not enough to ask whether the vendor is “secure.” Ask how customer data is segmented, whether support engineers can access production content, whether logs contain PHI, and whether the AI provider uses customer prompts for red-teaming or quality improvement. These questions are especially important when the vendor is also serving insurers, because insurer use cases may involve larger datasets and more downstream sharing. The goal is not to block innovation; it is to prevent hidden exposure.

4. Evaluate model access and model training rights

One of the most important AI-specific diligence questions is whether your clinic data can be used to train, fine-tune, or improve the vendor’s models. If the answer is yes, you need to know whether that happens by default, can be opted out of, and whether de-identification is truly irreversible. You also need to know whether human reviewers can see your data, because “not used for training” does not always mean “not viewed by humans.” This is where your contract needs explicit language, not assumptions.

Model access also matters from a governance standpoint. Can the vendor explain which model version produced a given output? Can they freeze a version for regulated workflows? Can they provide audit data showing which prompts generated which outputs? Those capabilities are essential when the AI output influences billing or patient communications. If the vendor uses an external model provider, request a subprocessor list and confirm the chain of data handling all the way down.

5. Test explainability and human oversight

Explainability in generative AI does not always mean the model is mathematically transparent. In practical terms, it means the vendor can tell you why a specific output was generated, what source data influenced it, and when a human must review it. For clinics, that matters if a generated summary is used for clinical routing, claims appeals, or patient messaging. You need enough visibility to detect errors, bias, and unsafe recommendations before they affect patients or revenue.

Ask vendors to show you sample audit trails, citation features, and confidence indicators. If the AI tool cannot cite source records or clearly label generated content, require a workflow where human staff validate all output before use. This approach mirrors the discipline used in on-device AI and other constrained environments: keep sensitive operations close to control, minimize ambiguity, and make overrides easy.

Contract language templates clinics can adapt

1. Data use and training restriction clause

Every AI-facing agreement should include a specific data use clause. The key idea is simple: the vendor may process your data only to provide the contracted service, and may not use PHI or patient data for model training, product development, benchmarking, or marketing unless you expressly agree in writing. If synthetic data is involved, the contract should explain whether the synthetic data is derived from your records and whether it can be reverse-engineered or retained after the engagement ends. In practice, the wording needs to be tighter than a generic privacy policy.

Template language: “Vendor shall process Customer Data solely to provide the services described in this Agreement. Vendor shall not use, disclose, retain, train on, fine-tune, validate, benchmark, or otherwise incorporate Customer Data, including any PHI, into any machine learning or generative AI model, dataset, or product improvement program except to the extent expressly authorized in a written amendment signed by both parties.”

2. Retention, deletion, and backup clause

Retention is one of the most common blind spots in AI contracts. Ask for a defined retention period for prompts, outputs, logs, and support data, and make sure deletion covers active systems, backups, and derivative artifacts where reasonably feasible. If the vendor cannot delete data from backups immediately, require a documented process and time frame. You should also require a certificate of deletion or written confirmation when termination occurs.

Template language: “Vendor shall retain Customer Data only for the minimum period necessary to perform the services and shall delete or return such data within thirty (30) days of request or termination, except where longer retention is required by law and specifically identified to Customer in writing. Vendor shall ensure deletion from production systems and shall describe its backup deletion schedule in the security exhibit.”

3. Synthetic data clause

Synthetic data can be valuable for testing, analytics, and product development, but only if the contract distinguishes legitimate de-identification from merely scrambled data. Clinics should require the vendor to disclose how synthetic data is generated, whether the source data is patient-derived, and what steps are taken to prevent re-identification. If the vendor uses synthetic data for model training, the contract should say whether the model can retain patterns from your patient population. That is especially important if the vendor serves insurers, because population-level inferences can still reveal sensitive operational insights.

Template language: “Any synthetic data derived from Customer Data shall be created using documented de-identification methods intended to prevent re-identification of individuals and shall not contain direct identifiers or reasonably linkable PHI. Vendor shall provide, upon request, a summary of the synthetic data generation method, validation approach, and re-identification risk controls.”

4. Explainability and audit rights clause

Explainability should be a contractual deliverable, not an aspirational promise. Your agreement should require the vendor to provide sufficient information for the clinic to understand how outputs are generated, how model versions are tracked, and how errors are investigated. You should also reserve audit rights for security, privacy, and compliance controls, especially when the vendor processes PHI on your behalf. A strong audit framework is similar to what careful operators use in AI governance programs: visibility is part of control, not a bonus feature.

Template language: “Vendor shall maintain records reasonably sufficient to demonstrate compliance with the privacy, security, and data governance obligations in this Agreement, including model versioning, access logs, prompt retention settings, and material incidents affecting Customer Data. Upon reasonable notice, Customer may review such records or obtain an independent third-party assessment report.”

What to ask vendors and insurers before you sign

Questions about data governance

Start with the basics, but make them specific. Ask whether the vendor has a formal data inventory, a data classification policy, and a documented retention schedule for AI inputs and outputs. Ask whether PHI is excluded from model training by default, whether customer data is segregated, and whether subprocessors are approved by contract. For insurers, ask how their AI system distinguishes between operational data, claims data, and clinical data, and whether those categories are handled differently. These are the same core controls that underpin third-party risk management across any sensitive system.

Questions about model operations

Ask what model family is used, how frequently it changes, and whether your outputs may change without notice. Ask whether prompt content is stored, whether outputs are used to improve the system, and whether the model provider has separate access to your data. Also ask how the vendor measures accuracy, bias, hallucination rates, and safety incidents. If they cannot answer clearly, they probably have not operationalized AI in a way that is safe enough for healthcare workflows.

Questions about regulatory readiness

Ask the vendor how it responds to HIPAA requests, breach notifications, record access requests, and deletion requests. Ask whether it supports role-based approvals for high-risk actions and whether it can separate human review from automated decisions. In the insurance context, ask how the AI workflow is documented for examiners and auditors, and whether the company has a process for updating disclosures as laws evolve. The clearest vendors will have a mature control set inspired by real-world lessons in regulatory change management, not just a glossy security page.

How to assess third-party risk in AI-enabled insurance workflows

Map the entire chain of custody

AI-enabled insurance workflows often involve the insurer, a claims processor, an AI platform, cloud hosting, data labeling services, document OCR, and support contractors. If any one of those parties has weak controls, your clinic can inherit the risk. Map the chain of custody for patient records, claim documents, notes, images, and correspondence. This is the same discipline used in supply chain continuity: resilience depends on understanding every handoff.

Classify the risk by workflow criticality

Not every AI workflow deserves the same level of scrutiny. A chatbot that helps patients locate office hours is lower risk than an AI system that drafts denial appeal language or summarizes charts for utilization review. Build a tiered classification model so that low-risk use cases can move faster while high-risk cases require legal, compliance, and technical approval. This reduces operational friction without lowering the bar where it matters.

Require incident escalation and remediation commitments

Your contract should specify response times for security incidents, data exposure, unauthorized model use, and material changes in subprocessors. It should also define who must notify whom, in what format, and within what time frame. A mature vendor will already have this machinery in place. A weak vendor will ask to “work it out later,” which is rarely acceptable when PHI is involved.

Comparison table: What to require, why it matters, and sample evidence

Due diligence area	Why it matters	What good looks like	Evidence to request	Red flag
Data use restriction	Prevents PHI from being used beyond the service	Explicit no-training, no-marketing clause	MSA, DPA, BAA, privacy exhibit	“We may use data to improve products”
Retention and deletion	Limits exposure after the business need ends	Defined retention period and deletion schedule	Retention policy, deletion SOP, backup schedule	No written retention standard
Synthetic data governance	Reduces re-identification and secondary-use risk	Documented generation method and validation	Method statement, DPIA/AI assessment, testing results	“Synthetic” with no explanation
Explainability	Supports human oversight and auditability	Citations, model versioning, review logs	Sample output logs, version history, audit trail	Black box with no traceability
Subprocessor control	Third parties may see or process PHI	Approved subprocessor list and notice rights	Subprocessor register, security attestations	No visibility into downstream vendors
Incident response	Fast containment reduces patient and regulatory harm	Clear notification timeframes and escalation path	IR plan, breach SLA, tabletop results	Best-effort notification language

How clinics should operationalize this checklist

Create a standard intake packet

Do not start from scratch with every vendor. Create a standard intake packet that includes a security questionnaire, HIPAA/BAA review, data flow diagram, AI use case description, subprocessors list, and contract redlines. This makes the review faster and more consistent. It also helps smaller clinics that do not have large compliance teams keep pace without burning out staff.

You can further streamline the process by building a simple internal rubric with pass, conditional pass, and fail categories. Vendors that score poorly on data use restrictions, retention, or explainability should not move forward until gaps are corrected. If your organization is also modernizing internal systems, compare this process with the operational logic in resilience planning: standardization speeds decisions and reduces surprises.

Require cross-functional signoff

AI vendor reviews should not live only in IT or procurement. Involve compliance, operations, legal, and the business owner for the workflow. If the vendor touches patient messaging or revenue cycle, bring in whoever owns patient experience and billing. The more the workflow resembles a patient-facing or claims-facing process, the more important it is to test the practical impact of AI errors.

One useful practice is to run a short tabletop exercise before go-live. Present a hypothetical incident: a vendor’s AI model retained patient prompts longer than expected, or an insurer used generated output in a claims decision that staff cannot explain. Ask who notices, who escalates, and what the communication path is. This kind of rehearsal is borrowed from high-risk access management and works just as well here.

Reassess after go-live

Vendor due diligence is not a one-time event. Once the system is live, monitor for scope creep, unexpected data sharing, new subprocessors, and changes in model behavior. Renewals are the perfect time to revisit contract terms and ask for updated security artifacts. If the vendor adds new AI features, your original review may no longer be sufficient. In other words, treat AI vendor management like a living control system, not a filing cabinet.

Practical examples clinics can learn from

Example 1: Patient messaging automation with insurer data

A multi-location clinic wanted an insurer-integrated AI tool to draft patient letters about coverage issues. The obvious benefit was speed, but the hidden risk was that the vendor wanted to retain prompts for quality improvement. The clinic required a BAA, a no-training clause, a 30-day deletion standard, and human approval before any message could be sent. They also required the vendor to document exactly which message templates used patient data and which did not. That is a classic example of combining contractual controls with workflow controls.

Example 2: Synthetic data for testing a billing workflow

A clinic group used synthetic data to test a billing integration with an AI-enabled clearinghouse. The vendor initially framed synthetic data as automatically safe, but the clinic asked for the generation method, validation tests, and a statement that source records would not be reconstructed or reused. After review, the clinic approved the use for test environments only, with strict separation from production. This avoided exposing live claims data during development while still allowing faster implementation.

Example 3: Insurer claims triage with explainability requirements

An insurer-facing workflow needed AI to triage incoming claims documents. Because the output could influence resolution timing, the clinic required the vendor to provide confidence indicators, citation links to source documents, and audit logs showing why a document was routed to a given queue. That made the system usable for operations without creating an opaque decision machine. It also reduced the risk of staff relying on a hallucinated summary when a human review was necessary.

FAQ: Vendor due diligence for generative AI

1) Do we need a BAA if the vendor says the AI feature does not “store” PHI?

Often yes, if the vendor creates, receives, maintains, or transmits PHI on your behalf. “Not storing” is not the same as not processing. If prompts, logs, outputs, or support interactions involve PHI, you should review the arrangement as a HIPAA matter and document it accordingly.

2) Is synthetic data automatically safe for compliance?

No. Synthetic data can still carry re-identification risk, especially if it is derived from small patient populations or rare conditions. Ask how it is generated, whether it can be linked back to individuals, and whether any raw source data is retained. Safe use requires validation, not just labeling.

3) What if the vendor says the model is “black box” and cannot be explained?

Then you need compensating controls. Require human review before important actions, tighter logging, restricted use cases, and a contract that forbids autonomous decisions in high-risk workflows. If the use case is too sensitive to be explained, it may be too sensitive to deploy.

4) Should clinics allow vendors to use data for product improvement?

Not by default. For PHI-bearing workflows, product improvement should be opt-in, narrowly scoped, and documented in writing. Many clinics will decide the answer is no, especially where patient trust or regulated records are involved.

5) What is the biggest mistake clinics make in AI vendor due diligence?

Assuming generic vendor security review is enough. Generative AI introduces model training, retention, explainability, and prompt/response risks that ordinary SaaS questionnaires often miss. The best programs treat AI as its own category of third-party risk.

6) How often should we re-review an AI vendor?

At least annually, and sooner if the vendor changes models, subprocessors, data retention practices, or the scope of use. For high-risk workflows, re-review at renewal and after any material product update.

Conclusion: protect the workflow, not just the contract

Generative AI can help clinics work faster, communicate better, and reduce administrative burden—but only if the data governance is real. The strongest vendor due diligence programs combine clear scope definition, strict contract language, practical technical controls, and ongoing monitoring. That approach protects patient trust while still allowing the organization to benefit from modern automation. It also puts you in a stronger position with insurers and third parties because your requirements are explicit, defensible, and easy to enforce.

If you are building your evaluation process now, start with the operational fundamentals: define the use case, demand written answers, require no-training and deletion terms, and insist on explainability for any workflow that affects patients or claims. Then use the same rigor you would apply to any critical infrastructure change. The clinics that win with generative AI will not be the ones that adopt it fastest; they will be the ones that govern it best. For broader context on AI in operations, you may also find value in on-device AI approaches, AI agent orchestration, and executive data governance strategies.

Contract Clauses and Technical Controls to Insulate Organizations From Partner AI Failures - A practical playbook for reducing exposure when AI vendors break expectations.
Elevating AI Visibility: A C-Suite Guide to Data Governance in Marketing - Useful governance patterns that translate well to healthcare and payer workflows.
Securing Third-Party and Contractor Access to High-Risk Systems - Strong access-control lessons for sensitive clinical integrations.
End-to-End CI/CD and Validation Pipelines for Clinical Decision Support Systems - A validation mindset clinics can apply to AI-enabled workflows.
The Evolution of On-Device AI: What It Means for Mobile Development - Helpful context on keeping sensitive processing closer to the edge.

Jordan Mitchell

Senior Healthcare Compliance Editor

Senior editor and content strategist. Writing about technology, design, and the future of digital media. Follow along for deep dives into the industry's moving parts.